Send to

Choose Destination
Gynecol Oncol. 2017 Sep;146(3):560-565. doi: 10.1016/j.ygyno.2017.07.006. Epub 2017 Jul 11.

Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.

Author information

Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil; Clínica Multihemo/Oncoclínicas do Brasil, Recife, Brazil. Electronic address:
Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil; Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro -, Brazil.
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil; Faculdade Pernambucana de Saúde, Recife, Brazil.
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Brazil.
D'or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.



Cervical cancer is a global public health challenge. Since 1999, platin based chemoradiation (CRT) is the standard treatment for those patients with locally advanced disease. However, this population still has a dismal prognosis and, alternatives approaches such as adjuvant chemotherapy are controversial, especially because of increased toxicity. Neoadjuvant chemotherapy (NACT) could be an option for more intensive treatment with manageable toxicity.


A phase II, prospective, non-randomized trial was conducted at a reference center in Recife, Brazil. Locally advanced cervical cancer patients (Ib2-IVa) were treated with neoadjuvant cisplatin 35mg/m2 and gemcitabine 1000mg/m2 D1 and D8, for 2cycles. Then, they received CRT (50.4Gy) with weekly cisplatin 40mg/m2 followed by brachytherapy. Response rate (RR) and toxicity were the primary endpoints. Progression-free survival (PFS) and overall survival (OS) were secondary endpoints.


Between Sep/2013 and Oct/2015, 50 patients were initiated on NACT and CRT. RR was 81% at the end of treatment. Hematological and gastrointestinal toxicity were most common. Grade 3/4 toxicity was 20% during NACT and 44% during CRT. Late adverse events were present in 20% of patients. PFS at 1 and 3-years were 73.4% (IC 58.7-83.6) and 53.9% (IC 36.9-68.3), respectively; and, OS at 1 and 3-years were 93.9% (IC 82.4-98.0) and 71.3% (IC 53.3-83.3), respectively.


In our hands NACT in locally advanced cervical cancer patients did not show a meaningful improvement in ORR. Nevertheless, we believe it should be further explored in prospective trials.


Cervical neoplasia; Chemotherapy; Clinical trial; Gemcitabine; Neoadjuvant therapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center